美国Synthetic Biologics  
Synthetic Biologics, Inc(SYN.US)成立于2001年，原名「Adeona Pharmaceuticals」，总部位于美国密西根州安娜堡，为一家生物合成制药公司，主要从事研究及开发肺动脉高压(PAH)、多发性硬化症、纤维肌痛，以及俗称「渐冻人」的肌萎缩性脊髓侧索硬化症(ALS)之治疗药物。

Founded in 2001 with headquarters in Ann Arbor, Michigan, and offices in Rockville, Maryland, Synthetic Biologics, Inc. (NYSE Amex: SYN) is a biotechnology company focused on the development of product candidates to address serious diseases and unmet medical needs.

Synthetic Biologics is focused on the development of synthetic biologics, an emerging biological discipline that combines biology, engineering and informatics for the development of new therapeutic candidates. To this end, the Company has entered into two worldwide exclusive channel collaborations with Intrexon Corporation that allow for the utilization of Intrexon’s comprehensive suite of proprietary technologies and processes. Pursuant to the most recent collaboration, Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. The initial collaboration is focused on development and commercialization of a DNA-based therapeutic for the treatment of pulmonary arterial hypertension (PAH).
In addition, Synthetic Biologics is developing, or has partnered the development of, funded clinical programs to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia (partnered with Meda AB).